News and Announcements
Proteomics Investigates Biomarkers for Mesothelioma
- Published September 08, 2016 4:53PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
6th September 2016, ASX Announcement
- PILL commences the search for protein biomarkers in the blood that could be used to diagnose mesothelioma.
- World Health Organisation estimates put the cost of treatment, compensation and settlement upwards of AU$667,00 for every sufferer.
- Mesothelioma kills 59,000 people annually.
Perth life sciences company Proteomics International Laboratories Limited (PILL, ASX: PIQ) has begun the detailed search for proteins associated with asbestos mesothelioma.
The research aim to develop a simple blood test for the disease, which could lead to early diagnosis for some of the many thousands of currently undiagnosed people who will die from mesothelioma each year.
To view the full announcement, please click on the button below.